Ambrx

FDA grants ARX788 fast track designation for HER2-positive metastatic breast cancer
FDA grants ARX788 fast track designation for HER2-positive metastatic breast cancer
Pharmaceutical Business Review
Ambrx
FDA
ARX788
HER-2 postive breast cancer
fast tack
Flag link:
$200M investment to advance clinical programs for Ambrx
$200M investment to advance clinical programs for Ambrx
MedCity News
Ambrx
oncology
Astellas
BeiGene
Bristol-Myers Squibb
Flag link:
Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx
Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx
Endpoints
BeiGene
China
Ambrx
Flag link:
Chinese drugmakers snag antibody expert Ambrx in joint buyout
Chinese drugmakers snag antibody expert Ambrx in joint buyout
Fierce Biotech
China
Ambrx
M&A
Fosun Pharmaceutical
WuXi PharmaTech
Flag link:
Bristol-Myers' armed antibody partner Ambrx shoots for an $86M IPO
Bristol-Myers' armed antibody partner Ambrx shoots for an $86M IPO
Fierce Biotech
IPOs
Bristol-Myers Squibb
Ambrx
Flag link:
China Biotech Week In Review: Pfizer's Attempt To Acquire AstraZeneca Could Run Into Trouble
China Biotech Week In Review: Pfizer's Attempt To Acquire AstraZeneca Could Run Into Trouble
Seeking Alpha
Pfizer
AstraZeneca
Zhejiang Hisun Pharma
Ambrx
Sinovac Biotech
Hutchison MediPharma
TaiGen Biotechnology
WuXi PharmaTech
Concord Medical Services
Flag link:
Pulse of J.P. Morgan 2014: Interviews with 17 biopharma execs
Pulse of J.P. Morgan 2014: Interviews with 17 biopharma execs
Fierce Biotech
JPMHC 2014
Algeta
Macrogenics
Xencor
Acetylon
Enanta Pharmaceuticals
Clinigen
Iroko Pharmaceuticals
Protalix BioTherapeutics
Ambrx
Roche
Sialix
Verastem
pRED
Cubist Pharmaceuticals
Celgene
Otonomy
Lumena Pharmaceuticals
Flag link:
Merck in potential $300M research deal with Ambrx
Merck in potential $300M research deal with Ambrx
Yahoo/AP
Ambrx
Merck
R&D
Flag link:
Bristol-Myers Signs Deal
Bristol-Myers Signs Deal
Yahoo/Zacks
Bristol-Myers Squibb
Ambrx
Fibroblast Growth Factor 21
FGF-21
Relaxin
diabetes
Flag link:
Bristol pays $24M for early-stage biotech drugs
Bristol pays $24M for early-stage biotech drugs
Yahoo/AP
Bristol-Myers Squibb
Ambrx
Relaxin
fibroblast activation protein
Flag link:
Ambrx, Wyeth ink antibody dev. deal
Ambrx, Wyeth ink antibody dev. deal
Fierce Pharma
Wyeth
Ambrx
antibody discovery
partnerships
Flag link: